Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics is attractive because its LUNAR platform and approved partnered COVID vaccine Kostaive de-risk the core delivery technology, while also validating self-amplifying mRNA with superior efficacy at a lower dose and strengthening partnership optionality. Its lead rare-disease programs show encouraging biomarker trends, with ARCT-810 reducing or maintaining ammonia in range and lowering glutamine despite small samples and diet changes, and the updated OTC thesis supports a higher probability of success from 25% to 35%. The next-gen ARCT-2601 could further improve dosing convenience and safety, with about 38x higher OTC protein expression in NHPs, while the Thermo Fisher collaboration offsets development costs and supports ARCT-032 in cystic fibrosis.

Arcturus Therapeutics is facing a negative fundamental setup because greater-than-expected operating expenses and cash burn may force more frequent equity issuances at less attractive valuations, pressuring shareholder returns. Its development outlook also appears fragile, as the translatability of preclinical superiority into clinical success remains uncertain and could delay programs if clinical signals on glutamine and ammonia levels are not replicated or improved. In addition, competition from gene-agnostic and gene editing approaches, alongside potentially disappointing clinical data or FDA and EMA requirements, raises the risk that small-patient-population revenue will be insufficient to offset rising costs and support meaningful returns on invested capital.